Royalty Pharma plc (RPRX) Stock Score, Valuation & Financial Research
Royalty Pharma plc is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 32/100.
Quick answer for RPRX
Royalty Pharma plc currently has a Wall Street Score of 32/100. The stored market price is $58.61. Its financial score is 40/100. Its valuation score is 16/100. These figures are a research snapshot, not a buy or sell recommendation.
What Royalty Pharma plc does
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX financial snapshot
- Wall Street Score:
- 32/100
- Current price:
- $58.61
- Market capitalization:
- $25.98B
- Revenue:
- $2.44B
- Net income:
- $827.6M
- Free cash flow:
- $2.49B
- Cash:
- $586.4M
- Total debt:
- $8.96B
- EPS:
- 2.33
- P/E ratio:
- 25.2x
- Financial score:
- 40/100
- Valuation score:
- 16/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $2.49B, showing positive cash generation.
- The balance sheet shows $586.4M of cash versus $8.96B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 40/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research RPRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.